Boston Scientific (BSX) Revenue (2009 - 2026)

Boston Scientific (BSX) has 18 years of Revenue data on file, last reported at $5.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 11.58% year-over-year to $5.2 billion; the trailing twelve-month figure through Mar 2026 stood at $20.6 billion (up 17.44% YoY), and the FY2025 full-year result was $20.1 billion, up 19.87% from the prior year.
• Revenue eased to $5.2 billion in Q1 2026, from $5.3 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $5.3 billion in Q4 2025 to a low of $3.0 billion in Q1 2022.
• A 5-year average of $4.1 billion and a median of $3.9 billion in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue grew 3.68% in 2022 and grew 22.84% in 2025, its largest moves.
• Tracing BSX's Revenue over 5 years: stood at $3.2 billion in 2022, then advanced by 14.9% to $3.7 billion in 2023, then climbed by 22.44% to $4.6 billion in 2024, then gained by 15.9% to $5.3 billion in 2025, then dropped by 1.57% to $5.2 billion in 2026.
• Business Quant data shows BSX's Revenue at $5.2 billion in Q1 2026, $5.3 billion in Q4 2025, and $5.1 billion in Q3 2025.